TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25881751
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg test formulation (one 400-mg tablet)
Study: 25881751
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg reference formulation (four 100-mg tablets)
Study: 24666765
Drug: Tadalafil (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (2.5 mg titrated to 5 mg or 5 mg)
Study: 24666765
Drug: Tadalafil (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (2.5 mg titrated to 5 mg or 5 mg) with IIEF-EF score ≥ 26
Study: 24666765
Drug: Tadalafil (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (2.5 mg titrated to 5 mg or 5 mg) achieving minimal clinically important difference in IIEF-EF score
Study: 11798515
Drug: Amifostine at
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amifostine at 740 mg/m(2)
Study: 9093983
Drug: High-volume nasogastric
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume nasogastric balanced polyethylene glycol electrolyte lavage (20 ml/kg/h) until the effluent was clear (n = 15)
Study: 9093983
Drug: Low-volume sodium
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume sodium phosphate solution (22.5-45 ml) separated by oral fluid intake (n = 14)
Study: 2282101
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (5 g of n‐3 fatty acids daily for 30 days)
Study: 2282101
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 wheat germ oil capsules daily for 30 days)
Study: 7023599
Drug: Primary closure
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary closure with topical ampicillin powder
Study: 26398887
Drug: Ezetimibe plus
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe plus high-potency statin (10mg atorvastatin or 1mg pitavastatin)
Study: 26398887
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose statin (20mg atorvastatin or 2mg pitavastatin)
Study: 25969561
Drug: 1 or
Normalized name: G-1 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 or 2 doses of inactivated hepatitis A vaccine (Healive)
Study: 25969561
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of live attenuated hepatitis A vaccine (Biovac)
Study: 21148807
Drug: initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: initial treatment group assignment
Study: 21148807
Drug: antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: antidepressant medication use during follow-up
Study: 7903921
Drug: Methotrexate, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate, 15 mg/wk
Study: 1095965
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg S‐adenosylmethionine (SAMe) plus 6000 gamma/day of Vitamin B12
Study: 25498469
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran extract (WBE) 10 g/d
Study: 25498469
Drug: Placebo (maltodextrin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin, 10 g/d)
Study: 23527300
Drug: CCX282-B 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCX282-B 500 mg once daily
Study: 23527300
Drug: CCX282-B 250
Normalized name: amphotericin B 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCX282-B 250 mg once daily
Study: 23527300
Drug: CCX282-B 250
Normalized name: amphotericin B 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCX282-B 250 mg twice daily
Study: 12921628
Drug: Short-term lactulose
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term lactulose (15 - 90 ml/d for 8 weeks)
Study: 12921628
Drug: Long-term lactulose
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term lactulose (15 - 90 ml/d for 24 weeks)
Study: 10699232
Drug: Verapamil-Magnesium Oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil-Magnesium Oxide (V-M) combination
Study: 10699232
Drug: Verapamil-Placebo (V-P)
Normalized name: P.V.P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil-Placebo (V-P) combination
Study: 9088585
Drug: Timolol 10
Normalized name: timolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 10 mg twice daily for 14 days
Study: 7655642
Drug: GH in
Normalized name: High incidence antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH in daily injections (0.125 IU.kg‐1. week‐1 for the first 4 weeks and subsequently 0.25 IU.kg‐1. week‐1)
Study: 2660871
Drug: Sultamicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sultamicillin (500 mg every 12 h)
Study: 2660871
Drug: Amoxicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (500 mg every 8 h)
Study: 31781802
Drug: Adductor canal
Normalized name: Canalevia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adductor canal block (ACB) with 0.3% ropivacaine 30 ml at mid-thigh adductor canal
Study: 31781802
Drug: Femoral nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoral nerve block (FNB) with 0.3% ropivacaine 30 ml at the thigh root-femoral nerve
Study: 20581700
Drug: L-arginine (ARG;
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (ARG; 2 × 6 g·d)
Study: 16599051
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg epinephrine + 4 ml hypertonic (3%) saline
Study: 16599051
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg epinephrine + 4 ml normal (0.9%) saline
Study: 10674281
Drug: GHB (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB (25 mg/kg body weight p.o.)
Study: 10674281
Drug: Pirenzepine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (100 mg p.o. 2 h before GHB)
Study: 9353508
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate 200 micrograms twice daily for 6 months
Study: 2996816
Drug: Combined radio-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined radio- and chemotherapy (CCNU) after surgical resection
Study: 30063658
Drug: Control (saline)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (saline) infusion
Study: 27430558
Drug: Instruction about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instruction about treatment
Study: 24262109
Drug: Intravenous acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acetazolamide (5mg/kg) in patients undergoing retinal detachment surgery
Study: 24262109
Drug: Intravenous acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acetazolamide (5mg/kg) in patients undergoing epiretinal membrane peeling
Study: 15921774
Drug: Methylphenidate (therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (therapeutic dose)
Study: 11957163
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of alfentanil and sufentanil (induction with alfentanil 15 microg/kg, maintenance with sufentanil 1 microg/kg/hr)
Study: 10980844
Drug: Thrombolytic agents
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic agents (streptokinase, tissue-type plasminogen activator)
Study: 10980844
Drug: New thrombolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New thrombolytic agents
Study: 2371814
Drug: Kennedy Ligament
Normalized name: human ligament preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kennedy Ligament Augmentation Device (LAD)
Study: 2257866
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg noscapine tablet
Study: 2257866
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg noscapine tablet
Study: 2257866
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg noscapine tablet
Study: 2257866
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg noscapine solution
Study: 2257866
Drug: Repeated administration
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated administration of noscapine tablets and solution
Study: 7149946
Drug: Integrated behavioral‐physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated behavioral‐physical therapy treatment program including electromyographic feedback
Study: 7149946
Drug: Standard exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard exercise physical therapy program
Study: 25576687
Drug: Metoclopramide nasal
Normalized name: metoclopramide Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide nasal spray 14 mg
Study: 24142299
Drug: Rilpivirine/emtricitabine/tenofovir disoproxil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilpivirine/emtricitabine/tenofovir disoproxil fumarate (25/200/300 mg) with standard meal (540 kcal, 21 g fat)
Study: 24142299
Drug: Rilpivirine/emtricitabine/tenofovir disoproxil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilpivirine/emtricitabine/tenofovir disoproxil fumarate (25/200/300 mg) with light meal (390 kcal, 12 g fat)
Study: 24142299
Drug: Rilpivirine/emtricitabine/tenofovir disoproxil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilpivirine/emtricitabine/tenofovir disoproxil fumarate (25/200/300 mg) under fasted conditions
Study: 19382202
Drug: Topical Tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Tretinoin Chemoprevention
Study: 15522370
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone acetonide injection (0.1 ml)
Study: 19206044
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone acetonide injection
Study: 15522370
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection (subconjunctival saline)
Study: 9248828
Drug: Treatment program
Normalized name: ZO Skin Health Acne Prevention Plus Treatment Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment program (12 weeks)
Study: 16822114
Drug: Behavioral couples
Normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral couples therapy plus individual‐based treatment (BCT)
Study: 16822114
Drug: Individual‐based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual‐based treatment only (IBT)
Study: 16822114
Drug: Psychoeducational attention
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Psychoeducational attention control treatment (PACT)
Study: 9081269
Drug: 7.6% carbohydrate-electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.6% carbohydrate-electrolyte (CE) solution
Study: 29972213
Drug: Auraptene enriched
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Auraptene enriched test juice (6.0 mg/day)
Study: 24473387
Drug: Standard continuous
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard continuous blood purification with heparin anticoagulation
Study: 22392567
Drug: Low plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low plasma concentration of DEX (0.04 ng/mL)
Study: 22392567
Drug: High plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: High plasma concentration of DEX (0.08 ng/mL)
Study: 10587413
Drug: Montelukast sodium
Normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast sodium therapy for 4 weeks
Study: 10587413
Drug: Montelukast sodium
Normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast sodium therapy (post-treatment)
Study: 10587413
Drug: Montelukast sodium
Normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast sodium therapy
Study: 8692528
Drug: IL-2 preoperative
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 preoperative therapy (18.10(6) IU/day subcutaneously for 3 consecutive days)
Study: 8692528
Drug: IL-2 preoperative
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 preoperative therapy
Study: 8692528
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no IL-2 preoperative therapy)
Study: 1748776
Drug: Extradural buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural buprenorphine 0.3 mg
Study: 1748776
Drug: Extradural pentazocine
Normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extradural pentazocine 30 mg
Study: 6632727
Drug: Dimethylbiguanide (DMB)
Normalized name: Dimethylbiguanid
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dimethylbiguanide (DMB) in doses of between 1 and 3 g
Study: 28622048
Drug: TCZ‐SC 162
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCZ‐SC 162 mg qw monotherapy
Study: 28622048
Drug: TCZ‐SC 162
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCZ‐SC 162 mg q2w monotherapy
Study: 25315686
Drug: Powerade (Coca
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powerade (Coca Cola Ltd); 129 kJ.100 mL(‐1)
Study: 25315686
Drug: Sustagen Sport
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustagen Sport (Nestle); 417 kJ.100 mL(‐1)
Study: 25315686
Drug: Soy milk
Normalized name: DIMETHICONE 4 g in 100 g CUTANEOUS PATCH [FERMENTED SOY MILK WRINKLE CARE SLEEPING MASK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy milk (273 kJ.100 mL(‐1))
Study: 25315686
Drug: Cow's milk
Normalized name: Cow's milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cow's milk (286 kJ.100 mL(‐1))
Study: 19076245
Drug: Daily hygiene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily hygiene with a soft toothbrush and toothpaste (G1)
Study: 19076245
Drug: Daily hygiene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily hygiene with a soft toothbrush and toothpaste plus immersion in sodium hypochlorite 0.5% for 20 min once a week (G2)
Study: 17499654
Drug: Ketamine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.2 mg x kg(‐1) intravenous over 10 minutes)
Study: 17499654
Drug: Placebo (isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (isotonic sodium chloride solution)
Study: 11980113
Drug: Ventolin nebulizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventolin nebulizer (2.5 mg)
Study: 11980113
Drug: Berodual (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berodual (0.25 mg ipratropium bromide and 0.5 mg phenoterol)
Study: 11980113
Drug: Atrovent (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrovent (0.5 mg)
Study: 11980113
Drug: Berotek (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berotek (1.0 mg by nebulizer Pulmo-Aide 56501)
Study: 11980113
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of beta 2‐adrenomimetic with atrovent
Study: 9531685
Drug: Sennosides (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sennosides (1 ml/kg, max 75 ml of syrup containing 2.0 mg/ml sennoside A and B)
Study: 9531685
Drug: Lavage solution
Normalized name: Colonic Lavage Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavage solution only
Study: 9098257
Drug: Aminocaproic acid
Normalized name: Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminocaproic acid (100 mg/kg every 4 hours; maximum 30 g daily)
Study: 2523658
Drug: Isradipine 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 5.0 mg
Study: 2523658
Drug: Isradipine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 7.5 mg
Study: 329946
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy for six 12-week courses
Study: 329946
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of maintenance chemotherapy for a further six 12-week courses
Study: 30054228
Drug: Pulsed field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed field gel electrophoresis (PFGE) analysis with XbaI
Study: 30054228
Drug: Pulsed field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed field gel electrophoresis (PFGE) analysis with BlnI
Study: 26188663
Drug: High methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High methadone dose (100 mg/day)
Study: 26188663
Drug: Low methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low methadone dose (10-25 mg/day)
Study: 21469942
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL syringe
Study: 21469942
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL syringe
Study: 23883424
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL syringe
Study: 21469942
Drug: Various syringe
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various syringe sizes (1, 3, 5, 10, 20, 60 mL)
Study: 19644851
Drug: Oral bovine
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral bovine type I collagen
Study: 11728835
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate at low plasma levels (0.1-0.3 ng/ml)
Study: 11728835
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate at medium plasma levels (0.3-0.6 ng/ml)
Study: 11728835
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate at high plasma levels (0.6-1.0 ng/ml)
Study: 7657402
Drug: Clinically-guided self-help
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinically-guided self-help (CGSH) program plus standard treatment (methadone maintenance plus individual counseling)
Study: 7657402
Drug: Didactic lecture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didactic lecture program plus standard treatment
Study: 30904909
Drug: Endobronchial autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endobronchial autologous blood plus thrombin patch (ABP)
Study: 23636085
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration treatment during 17 sessions
Study: 21612611
Drug: K‐134 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: K‐134 50 mg
Study: 21612611
Drug: K‐134 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: K‐134 100 mg
Study: 21612611
Drug: K‐134 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: K‐134 25 mg
Study: 15674004
Drug: Reiki treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reiki treatment by experienced Reiki practitioner
Study: 15674004
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment by a person with no knowledge of Reiki
Study: 15674004
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (rest only)
Study: 7484044
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl 100 micrograms.h‐1
Study: 7029297
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy regimens, 'pulse' VAC alone or VAC combined with adriamycin followed by irradiation (group III)
Study: 31651889
Drug: High-dose HT047
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose HT047 (750 mg 3 times a day)
Study: 31651889
Drug: Low-dose HT047
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose HT047 (500 mg 3 times a day)
Study: 24354616
Drug: Intradermal PRP
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal PRP after FCL
Study: 24354616
Drug: Topical PRP
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical PRP after FCL
Study: 19301380
Drug: Helicobacter pylori
Normalized name: HELICOBACTER PYLORI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helicobacter pylori eradication treatment (standard protocol)
Study: 2063854
Drug: No specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific treatment (control group)
Study: 17133405
Drug: Decitabine 100
Normalized name: cedazuridine-decitabine 100 mg-35 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decitabine 100 mg/m(2) per course every 4 weeks in 3 different schedules: 1) 20 mg/m(2) intravenously daily x 5, 2) 20 mg/m(2) subcutaneously daily x 5, and 3) 10 mg/m(2) intravenously daily x 10
Study: 15170007
Drug: Isotretinoin, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin, 0.5 mg/kg daily for 12 weeks
Study: 29080299
Drug: Telbivudine-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine-based therapy
Study: 24325953
Drug: Patient‐controlled anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient‐controlled anesthesia device delivering intravenous opioids (Control)
Study: 15876979
Drug: Dihydropyridine calcium
Normalized name: 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydropyridine calcium antagonists (nitrendipine)